Furthermore, this also suggests that combining selinexor with a KRAS G12C inhibitor sotorasib may have synergistic efficacy in patients with cancer that have developed resistance to therapy with sotorasib (or other KRAS G12C inhibitors). The gene discussed is KRAS; the disease is cancer.